SCHEMBL6430171

SCHEMBL6430171

CN(C)B(B(C1c2ccccc2-c2ccccc21)N(C)C)C1c2ccccc2-c2ccccc21

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR3 P46089 2/20 0.52
SLC22A2 O15244 1/20 0.41
SLC22A3 O75751 1/20 0.41
KMT2A Q03164 2/20 0.40
HTR2A P28223 3/20 0.37
POLB P06746 2/20 0.35
ACHE P22303 2/20 0.34
CHRM2 P08172 1/20 0.34
HTR1A P08908 1/20 0.34
ADRA2A P08913 1/20 0.34
CHRM1 P11229 1/20 0.34
DRD1 P21728 1/20 0.34
SLC6A2 P23975 1/20 0.34
SLC6A4 P31645 1/20 0.34
ADRA1A P35348 1/20 0.34
OPRM1 P35372 1/20 0.34
DRD3 P35462 1/20 0.34
SLC6A3 Q01959 1/20 0.34
HRH3 Q9Y5N1 1/20 0.34
MEN1 O00255 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1478687 0.72 GPR3 (0.44) GPR3SLC22A2SLC22A3KMT2AHTR2A
SCHEMBL1509312 0.69 GPR3 (1.00) GPR3SLC22A2SLC22A3KMT2AHTR2A
SCHEMBL1044055 0.69 GPR3 (0.41) GPR3KMT2AHTR2APOLBACHE
SCHEMBL27462668 0.69 GPR3 (0.41) GPR3SLC22A2SLC22A3KMT2AHTR2A
SCHEMBL16632987 0.69 GPR3 (0.41) GPR3KMT2AHTR2APOLBMEN1
SCHEMBL29953549 0.69 GPR3 (0.41) GPR3KMT2AHTR2APOLBACHE
SCHEMBL28709520 0.67 GPR3 (0.95) GPR3SLC22A2SLC22A3KMT2AHTR2A
SCHEMBL6428369 0.66 KMT2A (0.40) GPR3SLC22A2SLC22A3KMT2AHTR2A
SCHEMBL6428815 0.66 GPR3 (0.39) GPR3SLC22A2SLC22A3KMT2AHTR2A
SCHEMBL29290193 0.65 GPR3 (0.67) GPR3SLC22A2SLC22A3KMT2AHTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6891005-B2 Bridged metal complexes for gas phase polymerizations BP CHEMICALS LIMITED (GB) 2005-05-10 US disclosed
US-20040010102-A1 Bridged ylide group containning metal complexes ROBERT BOSCH GMBH (DE) 2004-01-15 US disclosed
US-20030199650-A1 Bridged metal complexes for gas phase polymerizations BP CHEMICALS LIMITED 2003-10-23 US disclosed
EP-1119575-B1 BRIDGED METAL COMPLEXES DOW CHEMICAL CO (US) 2003-09-03 EP disclosed
EP-1328533-A1 BRIDGED YLIDE GROUP CONTAINING METAL COMPLEXES Dow Global Technologies Inc. (US) 2003-07-23 EP disclosed
US-6500949-B2 ALPHA-OLEFIN POLYMERIZATION CATALYST DOW GLOBAL TECHNOLOGIES INC. 2002-12-31 US disclosed
EP-1141034-B1 BRIDGED METAL COMPLEXES FOR GAS PHASE POLYMERIZATIONS BP CHEM INT LTD (GB) 2002-10-30 EP disclosed
US-20020098973-A1 Bridged gallium or indium containing group 4 metal complexes CAMPBELL RICHARD E (US) 2002-07-25 US disclosed
WO-2002034759-A1 BRIDGED YLIDE GROUP CONTAINING METAL COMPLEXES DOW GLOBAL TECHNOLOGIES INC. (US) 2002-05-02 WO disclosed
US-6376406-B1 COORDINATION POLYMERIZATION CATALYSTS FOR ALPHA-OLEFINS THE DOW CHEMICAL COMPANY 2002-04-23 US disclosed
US-20010025115-A1 Bridged metal complexes DOW GLOBAL TECHNOLOGIES LLC 2001-09-27 US disclosed
US-6284905-B1 GROUP 4 TRANSITION METAL COMPLEX CONTAINING A BORON OR ALUMINUM BRIDGING GROUP CONTAINING A NITROGEN CONTAINING ELECTRON DONATING GROUP, ESPECIALLY AN AMIDO GROUP; OLEFIN SOLUTION OR SLURRY POLYMERIZATION CATALYSTS THE DOW CHEMICAL COMPANY 2001-09-04 US disclosed
WO-2001058912-A1 DINUCLEAR GROUP 4 METAL BORON OR ALUMINUM BRIDGE CONTAINING ANSA-COMPLEXES THE DOW CHEMICAL COMPANY (US) 2001-08-16 WO disclosed
WO-2001046201-A1 GALLIUM OR INDIUM-BRIDGED GROUP 4 METAL COMPLEXES THE DOW CHEMICAL COMPANY (US) 2001-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010025115-A1 Bridged metal complexes SLC39A14, NBAS, MCM4 GPR3 4478/4885SLC22A2 2702/4885SLC22A3 2150/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.